Oxford BioMedica has signed its seventh licence agreement for its LentiVector technology with a Fortune 500 global biopharmaceutical company
The agreement provides the licensee with use of the company's proprietary LentiVector gene delivery system for research activities.
Oxford BioMedica will receive an upfront licence payment and an annual maintenance fee.
Oxford BioMedica's lentivirus-based gene delivery technology, known as LentiVector, is one of the most powerful technologies for the delivery of genes to a wide range of cell and tissue types.
The LentiVector technology has applications both in therapeutic products and as a drug discovery tool for target validation and the creation of targeted disease models.
Oxford BioMedica has a comprehensive portfolio of US and European patents that cover the technology.
The Company has an active licensing programme providing access to its LentiVector technology on a non-exclusive basis primarily.
Licensees and partners include Biogen Idec, Merck, Pfizer, and Viragen.
Oxford BioMedica recently entered a strategic alliance with Sigma-Aldrich for commercialisation of the LentiVector technology for the research and reagents market.
Commenting on the news Oxford BioMedica's senior vice president commercial development, Peter Nolan, said: "We are delighted to have secured our seventh licensee for the LentiVector gene delivery technology.
"The pharmaceutical and biotechnology industry increasingly recognises our gene delivery technology as the system of choice in research and drug discovery, which is reflected by the quality and growing number of licensees".
